* dopamine receptor antagonists
** receptor
D2
** low potency agents
*** [#B] ideal receptor occupancy
60-70%
** high potency agents
* side effects of typical anti-psychotics
** [#A] akathisia
- motor restlessness; /not anxiety or agitation/
- treatment---reduce dose or change drug; antiparkinsonian agents, propranolol, or benzodiazepines may help
* prediction of therapeutic dosing
- D2 antagonism
- the basis of the therapeutic benefit of antipsychotics is blocking D2
- preferential binding to D2---D2:D1 = 5:1 receptor occupancy
* schizophrenia
** pathophysiology
*** [#B] mesocortical
- hypoactive / hypofunctional
- negative symptoms
*** [#B] mesolimbic
- hyperactive / hyperfunctional
- positive symptoms
** therapeutics
*** acute
**** [#B] do not combine
IM Lorazepam + Olanzapine
*** drug classes
**** first generation antipsycotics
**** second generation antipsychotics
***** Abilify
****** brand
aripiprazole
****** black box warning
agranulocytosis
***** Saphris
****** brand
asenapine
***** Clozaril
****** brand
clozapine
****** [#A] monitoring
ANC...
- general population ≥ 1500 μL
- benign ethnic neutropenia ≥ 1000 μL
***** Fanapt
****** brand
iloperidone
***** Latuda
****** brand
lurasidone
***** Rexulti
****** brand
brexpiprazole
***** Zyprexa
****** brand
olanzapine
***** Seroquel
****** brand
quetiapine
****** [#B] adverse effects
- weight gain / metabolic syndrome
- sedation
****** monitoring
- increases LFTs
- requires hepatic dose adjustments
***** Invega
****** brand
paliperidone
****** counseling
tablet shell may appear in stool
****** [#B] pharmacology
active metabolite of risperidone; therefore, failure of risperidone may indicate failure of paliperidone
***** Risperdal
****** brand
risperidone
***** Geodon
****** [#B] therapeutic use
- *greatest risk of QT prolongation*
- weight neutral
- must use with 500 calories
****** brand
ziprasidone
***** Vraylar
****** brand
cariprazine
**** injectable antipsychotics
***** aripiprazole
***** risperidone
* bipolar
** lithium
*** [#A] mechanism of action
depletion of intracellular inositol
*** [#A] therapeutic range
0.6-1.2 mEq/L
*** TODO toxicity
*** TODO signs and symptoms (?)
